Omeros (OMER) Liabilities and Shareholders Equity (2010 - 2026)
Omeros (OMER) posted Liabilities and Shareholders Equity of $286.2 million for Q1 2026, down 12.12% sequentially from $325.6 million in Q4 2025, and up 21.69% YoY from $235.2 million in Q1 2025.
Analysis
Omeros (OMER) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Omeros has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $286.2 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 21.69% year-over-year to $286.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $998.1 million (down 15.55% YoY) and the FY2025 annual result came in at $325.6 million, up 17.52% from the prior year.
- Liabilities and Shareholders Equity eased to $286.2 million in Q1 2026 per OMER's latest filing, from $325.6 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $591.0 million in Q4 2022 and troughed at $185.7 million in Q3 2025.
- A 5-year average of $372.9 million and a median of $356.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 270.7% in 2022, then sank 46.25% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $591.0 million in 2022, then slumped by 35.99% to $378.3 million in 2023, then fell by 26.75% to $277.1 million in 2024, then grew by 17.52% to $325.6 million in 2025, then slipped by 12.12% to $286.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $286.2 million, $325.6 million, and $185.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | 286.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 286.83 Mn |
| Mar 31, 2026 | 286.17 Mn |
| Dec 31, 2025 | 325.63 Mn |
| Sep 30, 2025 | 185.71 Mn |
| Jun 30, 2025 | 200.57 Mn |
| Mar 31, 2025 | 235.16 Mn |
| Dec 31, 2024 | 277.08 Mn |
| Sep 30, 2024 | 313.34 Mn |
| Jun 30, 2024 | 356.31 Mn |
| Mar 31, 2024 | 437.49 Mn |
| Dec 31, 2023 | 378.27 Mn |
| Sep 30, 2023 | 493.07 Mn |
| Jun 30, 2023 | 527.42 Mn |
| Mar 31, 2023 | 560.13 Mn |
| Dec 31, 2022 | 590.97 Mn |
| Sep 30, 2022 | 457.55 Mn |
| Jun 30, 2022 | 345.64 Mn |
| Mar 31, 2022 | 369.26 Mn |
| Dec 31, 2021 | 419.27 Mn |
| Sep 30, 2021 | 123.43 Mn |